A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer

一项旨在最大程度地减少可手术乳腺癌患者对有氧训练无反应的随机试验

基本信息

  • 批准号:
    10599876
  • 负责人:
  • 金额:
    $ 68.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-04-16 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Cardiovascular disease (CVD) is the primary cause of late mortality (death ≥5 yrs from diagnosis) in early breast cancer (EBC). Effective treatment strategies that improve function across multiple systems are a major clinical need to reduce CVD in EBC. Aerobic exercise therapy (AT) is a pleiotropic intervention demonstrated in randomized controlled trials (RCTs) to improve cardiorespiratory fitness (CRF), a strong, independent predictor of CVD and all-cause mortality in BC and other malignancies. However, virtually all AT RCTs in oncology report the mean CRF change for the overall cohort; presentation of the mean result masks variability in responses. To directly address this gap, our group explored response variability in our recently completed RCT among 174 EBC patients (2.8 yrs. post-adjuvant therapy) who were allocated to 150 min/wk of: (1) linear AT (70% CRF); (2) nonlinear AT (55% to 100% CRF); or (3) stretching (attention control) for 16 consecutive wks. Despite high AT adherence, we found that: (1) CRF change ranged from -10% to +24%, and (2) ~60% were classified as CRF non-responders based on the CRF technical error (TE; a robust measure of biological variability and measurement error). These findings indicate that AT following the conventional volume (~150 min/wk) and / or length (~16 wks) is insufficient for improving CRF in a substantial proportion of EBC survivors. AT-induced improvement in CRF is associated with corresponding reductions in CVD risk; thus, there is a critical need to test the efficacy of alternative AT approaches that can optimize CRF response rate. Preliminary findings from our group, and others, indicate that in order to augment CRF, increased AT volume and / or length is required to allow for multisystem adaptation (i.e., across all components of the cardiopulmonary- vascular-muscular axis). There have been no RCTs directly assessing AT length and volume on CRF response rate in any cancer population. The objective of this study is therefore to evaluate the effects of AT program length and volume on CRF response rate and other pertinent outcomes in EBC. AIM 1: Compare the effects of nonlinear AT program length and volume on CRF response rates. AIM 2: Evaluate the effects on physiological determinants of CRF. AIM 3: Ascertain the difference in patient-reported outcomes, feasibility, and safety. Using a 4-arm RCT design, we will randomly allocate 152 (n=38/group) EBC survivors following completion of adjuvant therapy to: Arm A: volume only (300 min/wk for 16 weeks), Arm B: length only (150 min/wk for 32 weeks), Arm C: length and volume (300 min/wk for 32 weeks), or Arm D: control (150 min/wk for 16 weeks). IMPACT: Results from this investigation will identify the AT regimen that maximizes CRF response rate and other clinically relevant endpoints in EBC. Ultimately, these findings will inform policy, evidence-based guidelines, and standard clinical care.
项目摘要 心血管疾病(CVD)是早期死亡(诊断后≥5年死亡)的主要原因。 乳腺癌(EBC)。改善多系统功能的有效治疗策略是一个主要的 临床需要减少EBC中的CVD。有氧运动疗法(AT)是一种多效性干预, 改善心肺功能(CRF)的随机对照试验(RCT),这是一个强有力的独立预测因素 BC和其他恶性肿瘤的CVD和全因死亡率。然而,几乎所有肿瘤学的AT RCT 报告整个队列的平均CRF变化;平均结果的显示掩盖了 应答为了直接解决这一差距,我们小组在最近完成的随机对照试验中探索了反应的变异性 在174例EBC患者(辅助治疗后2.8年)中,分配至150 min/wk:(1)线性AT (70% CRF);(2)非线性AT(55%至100%CRF);或(3)拉伸(注意力控制)连续16周。 尽管AT依从性高,但我们发现:(1)CRF变化范围为-10%至+24%,(2)~60%为 根据CRF技术错误(TE;生物学的稳健测量)分类为CRF无应答者 可变性和测量误差)。这些结果表明,AT在常规容量(~150 min/wk)和/或长度(~16 wk)不足以改善相当大比例的EBC存活者的CRF。 AT诱导的CRF改善与相应的CVD风险降低相关;因此, 迫切需要测试替代AT方法的有效性,以优化CRF缓解率。初步 我们小组和其他人的研究结果表明,为了增加CRF,增加AT体积和/或 需要长度以允许多系统适配(即,心肺功能的所有组成部分- 血管-肌肉轴)。尚无直接评估CRF上AT长度和体积的RCT 任何癌症人群的反应率。因此,本研究的目的是评估AT的作用 项目长度和数量对CRF应答率和EBC中其他相关结局的影响。目标1:比较 非线性AT程序长度和体积对CRF应答率的影响。目标2:评估对 CRF的生理决定因素。目的3:确定患者报告结局、可行性 和安全性采用4组RCT设计,我们将随机分配152例(n=38/组)EBC幸存者, 完成辅助治疗:A组:仅容量(300分钟/周,持续16周),B组:仅长度(150分钟/周) 分钟/周,持续32周),C组:长度和体积(300分钟/周,持续32周),或D组:对照组(150分钟/周,持续32周) 16周)。影响:本研究的结果将确定最大化CRF缓解的AT方案 EBC中的发生率和其他临床相关终点。最终,这些发现将为政策提供信息, 指导方针和标准临床护理。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessica Scott其他文献

Jessica Scott的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jessica Scott', 18)}}的其他基金

Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial
原发性乳腺癌的灵活与标准有氧训练剂量:一项随机且适应反应的试验
  • 批准号:
    10708044
  • 财政年份:
    2022
  • 资助金额:
    $ 68.71万
  • 项目类别:
Flexible versus Standard Aerobic Training Dosing in Primary Breast Cancer: A Randomized and Response-Adapted Trial
原发性乳腺癌的灵活与标准有氧训练剂量:一项随机且适应反应的试验
  • 批准号:
    10502148
  • 财政年份:
    2022
  • 资助金额:
    $ 68.71万
  • 项目类别:
A Randomized Trial to Minimize Non-Response to Aerobic Training in Operable Breast Cancer
一项旨在最大程度地减少可手术乳腺癌患者对有氧训练无反应的随机试验
  • 批准号:
    10377998
  • 财政年份:
    2020
  • 资助金额:
    $ 68.71万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 68.71万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 68.71万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 68.71万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 68.71万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 68.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 68.71万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 68.71万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 68.71万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 68.71万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 68.71万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了